FDA-CDC Antimicrobial Resistance Isolate Bank: a Publicly Available Resource To Support Research, Development, and Regulatory Requirements

• Authors: Joseph Daniel Lutgring, Emory University; María-José Machado, Centers for Disease Control and Prevention; Faiza H. Benahmed, Food and Drug Administration; Patricia Conville, Food and Drug Administration; Ribhi M. Shawar, Food and Drug Administration; Jean Patel, Centers for Disease Control and Prevention; Allison Cory Brown, Emory University
• Journal Title: Journal of Clinical Microbiology
• Volume: Volume 56, Number 2
• Publisher: American Society for Microbiology | 2018-02-01, Pages e01415-17
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1128/JCM.01415-17
• Subjects: Biology, Microbiology; Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Microbiology; AR Bank; AR Isolate Bank; antimicrobial resistance; antibiotic resistance; SOCIETY

Abstract

The FDA-CDC Antimicrobial Resistance Isolate Bank was created in July 2015 as a publicly available resource to combat antimicrobial resistance. It is a curated repository of bacterial isolates with an assortment of clinically important resistance mechanisms that have been phenotypically and genotypically characterized. In the first 2 years of operation, the bank offered 14 panels comprising 496 unique isolates and had filled 486 orders from 394 institutions throughout the United States. New panels are being added.